Maternal hormonal contraception use and childhood cancer risk: a systematic review and meta-analysis
European Journal of Epidemiology · 2026
DOI: 10.1007/s10654-025-01335-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Epidemiology, 2026. Verfasst von Sif E Carlsen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Virus, Lifestyle and Genes, Danish Cancer Institute, DK-2100, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Neoplasms, Prenatal Exposure Delayed Effects, Hormonal Contraception, Contraceptives, Oral, Hormonal. Die Arbeit nennt 74 Literaturangaben.
Abstract (Originalsprache)
Observational studies have linked maternal hormonal contraception use to childhood cancer risk, but findings are inconsistent. A systematic review was conducted of this potential relationship. A systematic search was performed in PubMed, Embase, Scopus, Cochrane, and Web of Science databases until April 9, 2025. Studies reporting maternal hormonal contraception use before or during pregnancy and childhood cancer risk (0-19 years) were eligible. We included studies providing risk estimates in English or Scandinavian languages. Newcastle-Ottawa Scale was used to assess study quality. Meta-analysis using fixed and random effects was used to pool relative risks (RRs) with 95% confidence intervals (CIs) for childhood cancer according to maternal hormonal contraception use (1) up to or during pregnancy, and (2) exclusively during pregnancy. We included 27 studies (24 case-control and 3 cohort), totaling 11,067 childhood cancer cases. Maternal hormonal contraception use up to and during pregnancy increased risk of any childhood cancer (RR = 1.18; 95% CI = 1.10-1.26), leukemia (RR = 1.24; 95% CI = 1.06-1.45), and lymphoid leukemia (RR = 1.17; 95% CI = 1.06-1.28). Exposures during pregnancy showed higher risk estimate for any cancer (RR = 1.32; 95% CI = 1.12-1.56) and leukemia (RR = 1.63; 95% CI = 1.07-2.49). Most studies were moderate (70%) or high (26%) quality. Maternal hormonal contraception use may increase childhood cancer risk, particularly for leukemia, and during pregnancy. Further prospective studies are needed, focusing on specific hormonal contraception substances and exposure timing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virus, Lifestyle and Genes, Danish Cancer Institute, DK-2100, Copenhagen, Denmark.
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
- Department of Data and Analytics, Finnish Institute for Health and Welfare, Helsinki, Finland.
- Teratology Information Service, Emergency Medicine and Services, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
- Health and Medical Care Administration, Stockholm, Region Stockholm, Sweden.
Zitieren
APA
Carlsen, S. E., Jarden, E., Hemmingsen, C. H., Schmidt, L., Hjorth, S., Leinonen, M. K., Nörby, U., Mørch, L. S., Kjaer, S. K., Nordeng, H., & Hargreave, M. (2026). Maternal hormonal contraception use and childhood cancer risk: a systematic review and meta-analysis. European Journal of Epidemiology. https://doi.org/10.1007/s10654-025-01335-5
Vancouver
Carlsen SE, Jarden E, Hemmingsen CH, Schmidt L, Hjorth S, Leinonen MK, et al. Maternal hormonal contraception use and childhood cancer risk: a systematic review and meta-analysis. European Journal of Epidemiology. 2026. doi:10.1007/s10654-025-01335-5
BibTeX
@article{Carlsen2026,
author = {Carlsen, Sif E and Jarden, Emily and Hemmingsen, Caroline H and Schmidt, Lone and Hjorth, Sarah and Leinonen, Maarit K and Nörby, Ulrika and Mørch, Lina S and Kjaer, Susanne K and Nordeng, Hedvig and Hargreave, Marie},
title = {Maternal hormonal contraception use and childhood cancer risk: a systematic review and meta-analysis},
journal = {European Journal of Epidemiology},
year = {2026},
doi = {10.1007/s10654-025-01335-5}
}
EUVIMED